Case Report: Coexistence of Anti-AMPA Receptor Encephalitis and Positive Biomarkers of Alzheimer’s Disease

Yu Song 1†, Shanshan Chen 1†, Ju Gao 2, Jie Lu 1, Wenwen Xu 1, Xingjian Lin * and Jiu Chen 3,4*

1 Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China, 2 Department of Geriatric Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China, 3 Institute of Neuropsychiatry, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China, 4 Institute of Brain Functional Imaging, Nanjing Medical University, Nanjing, China

Anti–α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis is a rare autoimmune disease that is characterized by acute cognitive impairment, mental symptoms, and seizures. The high comorbidity rate between anti–AMPA receptor (AMPAR) encephalitis and other somatic diseases, such as malignancy, has revealed the possibility of potential copathogenesis. However, there have not yet been reports about anti-AMPAR encephalitis with concomitant cerebrospinal fluid (CSF) biomarkers consistent with Alzheimer disease (AD). Herein, we present the case of an elderly male patient with autoimmune encephalitis (AE) presenting with anti–AMPA1-R and anti–AMPA2-R antibodies, as well as CSF biomarkers of AD. The patient was hospitalized with acute memory decline for 1 week. Anti–AMPA1-R and anti–AMPA2-R antibodies were positively detected in CSF, and the anti–AMPA2-R antibody was also present in the serum. Additionally, the biomarkers of AD were concurrently present in CSF (Aβ1–42 = 245.70 pg/mL, t-Tau = 894.48 pg/mL, p-Tau = 78.66 pg/mL). After administering a combined treatment of intravenous immunoglobulin and glucocorticoids, the patient recovered significantly, and his cognitive function achieved a sustained remission during 2 months’ follow-up. This case raises the awareness of a possible interaction between AE and changes of CSF biomarkers. We speculated that the existence of AMPAR antibodies can induce changes of CSF, and other pathological alterations. This present report highlights that a potential relationship exists among AE and provides a warning when making the diagnosis of AD.

Keywords: autoimmune encephalitis, anti–α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, Alzheimer’s disease, cognitive impairment, cerebrospinal fluid biomarkers

BACKGROUND

Autoimmune encephalitis (AE) is defined as a group of important neurological inflammatory diseases with specific autoantibodies. The incidence of AE has increased to 1.2/100,000 person-years (2006–2015) compared to 0.4/100,000 person-years (1995–2005) (1). The rapid development of a spectrum of specific autoantibody-associated neurological disorders has...
deepened our understanding in the last 30 years. As one of the specific antibodies targeting neuronal surface antigens, which are more likely to be pathogenic, anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA1) antibody has rarely been seen in clinical practice. To date, ~60 related cases have been reported (2). Anti-AMPA1 encephalitis is characterized by diverse clinical manifestations, and ~60% of patients might be associated with malignancy (3). Coexisting antibodies, such as collapsin response mediator protein 5 antibody, have also been identified (4). Nevertheless, to the best of our knowledge, no case has ever been reported, comprising two positive subtypes of anti-AMPA1 antibodies and typical changes of biomarkers of Alzheimer disease (AD).

Herein, we report the case of a 79-year-old man diagnosed with anti-AMPA1 encephalitis with the coexistence of antibodies targeting AMPA1 receptor (AMPA1-R) and AMPA2 receptor (AMPA2-R) and positive cerebrospinal fluid (CSF) biomarkers of AD, manifested as rapidly progressive dementia. We aim to explore the underlying pathological mechanisms of AE and the CSF biomarkers of AD.

CASE PRESENTATION

A 79-year-old man was admitted to the Nanjing Brain Hospital with rapid memory decline for 1 week, which aggravated in the past 2 days on October 16, 2020. The patient especially had deficits in recent memory, such as forgetting what he had just done or said and occasionally did not recognize the family members. His symptoms were repetitive, with remissions and exacerbations. Two days before admission, the cognitive function had further declined, mainly manifested as failure to recognize family members and inability to take care of himself. Thus, he was admitted to the hospital, brought by his son. Five days after admission, the patient developed mental symptoms, the hallmark of which was visual hallucinations. The family members reported that the patient saw people or things that did not exist and mistook the hospital for the street. During the disease course, the patient did not undergo epileptic seizures.

The patient had a history of diabetes for 2 years, which was treated by the oral administration of metformin hydrochloride (Diaformin) tablets (1.0 g, twice a day) and acarbose tablets (50 mg, thrice a day). He also had hypertension for several years and was treated by the oral administration of telmisartan tablets (50 mg, once a day), with no history of anxiety, depression, or epilepsy. However, the blood sugar levels and blood pressure were well-controlled, with an average blood pressure of 136/92 mm Hg and fasting blood glucose of 5.89 mmol/L. The patient had no cough, coughing sputum, hemoptysis, and no enlargement of superficial lymph nodes throughout the body. Tumor markers were all normal. After consultation with a respiratory specialist, the tumor possibility was considered unlikely, and regular follow-up was recommended.

The results of autoimmune antibodies were available 5 days after admission; the patient was diagnosed with anti-AMPA1 encephalitis. The sign of the tumor was ruled out, and immunotherapy was initiated with intravenous methylprednisolone (500 mg/d) and immunoglobulin 0.4 g/kg per day for 5 days, and then methylprednisolone dose was gradually reduced. Two days later, an analysis of the CSF biomarkers showed amyloid and Tau abnormalities. Uncertain whether AE caused changes in the CSF biomarkers or whether there existed concomitant chronic cognitive decline, we planned to treat the patient with immunotherapy first and then determine the need for other drugs such as cholinesterase inhibitors based on the patient's subsequent recovery. Ten days after treatment, he recovered significantly but still suffered from mild memory impairment. Finally, he was discharged with 60 mg/d prednisone,
Caltrate, and potassium chloride sustained-release tablets to prevent the side effects of the glucocorticoid. Thirty days later, the patient's cognitive function improved as he scored 10/30 on MMSE and 7/30 on MoCA. During the 2-month follow-up, his prednisolone acetate tablets had been adjusted to 20 mg/d with cognitive scale assessment: MMSE: 15/30 and MoCA: 12/30. Five months after discharge, the patient stopped taking oral prednisolone and the related medications used to prevent the side effects of the glucocorticoid and scored 22/30 on MMSE, 20/30 on MoCA, and 0.5 on the clinical dementia rating. Confirmed by his son, the patient could live alone and forgot things occasionally. We recommended that the patient should still perform appropriate cognitive function exercises daily and be followed regularly, with additional pharmacological interventions if necessary. Figure 2 summarizes the clinical course. Details about the laboratory evaluations are presented in the Supplementary Material.

**DISCUSSION AND CONCLUSION**

Since the characterization of anti-NMDAR encephalitis in 2007, more types of AE have been explored. However, anti-AMPAR encephalitis is a relatively rare type. Because of a lack of relevant case reports and large-scale studies, the clinical manifestations and treatments have not been consistent (5). Although the core symptoms of anti-AMPAR encephalitis include cognitive impairment, mental symptoms, and seizures, some patients might present motor–sensory disturbances, ataxic gait, or
TABLE 1 | Test results of CSF biomarkers of AD.

| Test method          | Results         | Reference interval                                      |
|----------------------|-----------------|---------------------------------------------------------|
| ELISA Aβ<sub>1-42</sub> | ↓245.70 pg/mL   | ≤550 pg/mL Aggregated Aβ                                   |
|                      |                 | 551–650 pg/mL Suspicious                                 |
|                      |                 | ≥651 pg/mL Normal                                        |
| ELISA Aβ<sub>1-40</sub> | 8,046.11 pg/mL  | ≥7,000 pg/mL Normal                                       |
|                      |                 | ≤7,000 pg/mL Suspicious                                 |
| ELISA Aβ<sub>1-42/Aβ</sub> | ↓0.031         | ≤0.05 Positive                                           |
|                      |                 | >0.05 Negative                                           |
| ELISA t-Tau          | ↑894.48 pg/mL   | ≤399 pg/mL Normal                                        |
|                      |                 | >399 pg/mL Neurodegeneration or neuronal injury           |
| ELISA p-Tau          | ↑78.66 pg/mL    | ≤50 pg/mL Normal                                         |
|                      |                 | >50 pg/mL Neurofibrillary tangles                        |

CSF, cerebrospinal fluid; AD, Alzheimer disease; ELISA, enzyme-linked immunosorbent assay; Aβ, amyloid β-protein; t-Tau, total-Tau protein; p-Tau, phosphorylated-Tau protein. The method of the ELISA determinations can be seen in the Supplementary Material.

↓: decreased; ↑: increased.

**FIGURE 2** | Clinical course of the case.

a) Brain MRI: ischemic changes in centrum semiovale and corona radiate; b) Chest CT: a nodule within the upper lobe of the right lung; c) MMSE: 2/30; MoCA: 3/30

- A 5-day course of IV methylprednisolone 500mg/d and immunoglobulin G (4.6 g/L, normal range 0.20–0.40 g/L) was administered
- The dosage of IV methylprednisolone had been adjusted to 120mg/d and gradually reduced
- Take oral prednisone 60 mg/d
- Take oral prednisone 40 mg/d
- Take oral prednisone 20 mg/d
- Taking oral prednisone had stopped.
dizziness (6). Currently, immunocytochemistry on HEK 293 cells transfected with GluA1 and/or GluA2 subunits is mainly used to diagnose anti-AMPAR encephalitis (7). The main treatment includes first-line therapies, such as corticosteroids, intravenous immunoglobulin, and plasma exchange or immunoadsorption, and second-line regimens, such as mycophenolate, rituximab, and cyclophosphamide. For patients with tumor-associated AE, tumor-targeting treatment should be initially considered (8). A systematic review on anti-AMPAR antibody encephalitis suggested that 84% of patients achieved sustained improvement of symptoms, whereas several other studies reported high rates of neurological relapse (9). The patient in this case report had antibodies targeting AMPA1-R and AMPA2-R in the CSF, with AMPA2-R in the serum. After immunotherapy, the symptoms improved significantly.

AMPARs are heterotetramers composed of GluA1-A4 and mediate most of the fast excitatory synaptic transmission in the brain (2). AMPAR trafficking is a key mechanism that induces nascent synaptic development. The type, threshold, and extent of synaptic plasticity at any synapse are determined by the characteristics and properties of AMPAR (10). GluA1/A2 is primarily located in the limbic system and hippocampus, indicating that GluA1/A2 is closely associated with learning, memory, personality, and epilepsy. A study investigating the effect of AMPAR antibodies on the cultures of live rat hippocampal neurons revealed that the antibodies from patients could lead to a selective decrease in total surface area and synaptic localization of AMPARs, resulting in decreased inhibitory synaptic transmission and increased intrinsic excitability. Furthermore, these changes might be attributed to memory deficits and epilepsy (11). However, interestingly, more than half of the cases have been admitted to the hospital with an initial symptom of memory decline or cognitive impairment (5).

The patient only had rapid memory loss as the first symptom. Because of living separately from their parents, his children were not very aware of the patient’s condition in recent years. His wife reported that the patient forgot to buy things occasionally. In the last 2 years, but their life was not affected. Thus, AE was the tentative diagnosis; however, there was the possibility of AD or preclinical AD, with some factors leading to an acute exacerbation of the disease process. Testing CSF biomarkers is the main diagnostic tool for detecting AD, as positron emission tomography is expensive (12). Surprisingly, the patient had biomarkers suggestive of AD within the CSF (Aβ1–42↑, Aβ1–42↓, Aβ1–40↓, t-Tau↑, and p-Tau↑). According to the AT(N) system proposed by the 2018 National Institute on Aging and Alzheimer’s Association workgroup, the results were consistent with the biomarker category of AD (A+: aggregated Aβ, T+: neurofibrillary tangles, N+: neurodegeneration, or neuronal injury) (13).

Accumulating data suggest that AD is a continuous process, and the progression of biomarkers is also a continuum that begins before the onset of symptoms (13). AMPAR and AMPA signaling pathway disorders have been demonstrated to be particularly prominent in the pathogenesis of this continuous process. Changes in actin cytoskeleton integrity and the structure and number of dendritic spines, which occur early in AD, are associated with a decline in AMPA signaling. In addition, AMPA dysfunction correlates with the presence of soluble, but not insoluble, Aβ and Tau species (14). At the same time, anti-AMPAR antibodies can reduce the expression of AMPARs (11). It seems that the pathologic processes of AE and AD might affect each other. One previous study reported that the concentration of programulin could be a CSF biomarker of NMDAR-AE, and high levels of t-Tau might suggest a risk for hippocampal sclerosis (15). However, the available evidence can only demonstrate that either the presence of antibodies or neurodegeneration might be associated with AE; nevertheless, it is still necessary to show whether anti-AMPAR antibodies could cause a typical change in the CSF biomarkers of AD. Moreover, it should be noted that diabetes and hypertension are associated with neurodegeneration. Insulin resistance and decreased insulin activity can suppress protein kinase B signaling, leading to dephosphorylation and activation activity of glucose synthase kinase-3β, which is involved in Tau phosphorylation and formation of Aβ1–40 and Aβ1–42 (16). Cerebral ischemia can stimulate the expression of presenilin, which is involved in Aβ synthesis, leading to the accumulation of Aβ (17). Therefore, further investigations are necessary to determine whether there is a direct link between anti-AMPAR antibodies and alterations in AD pathologic changes or whether the presence of Aβ and p-Tau is a potential predisposing factor for AE.

Besides, it should be noted that patients with AE, who are associated with anti-AMPAR, usually exhibit limbic system involvement or temporomesial abnormality in brain MRI and slow waves or epileptic waves in EEG. Approximately 64% of cases are associated with tumors, while the current case exhibited normal brain MRI. A few cases with short memory loss or confusion as initial symptoms were reported to have normal MRI with normal or general slowing in EEG (3, 5). In this group of patients, especially those with subacute onset or longer duration of disease, the diagnosis seems to be confirmed only by determining autoimmune antibodies. The cognitive impairment in patients with AE or autoimmune dementia is manifested with a rapid disease process, whereas symptoms in patients with AD have a gradual on set over months to years (8). It is generally accepted that the pathogenesis of dementia, and AD, in particular, is associated with autoimmunity, including classic autoantibodies and functional autoantibodies (18). Therefore, we suggest that irrespective of whether anti-AMPAR antibodies are involved in pathologic changes of AD and whether patients with AE exhibit cognitive impairment, they could suffer from AD pathologic changes. However, limited reports are available on anti-AMPAR–associated autoimmune dementia, as well as the relationship between anti-AMPAR antibodies and the changes of CSF. Thanarajah et al. reported an atypical AE case with neuropil antibodies against an unknown epitope, increased Tau level, decreased level of amyloid ratio, and temporoporatelial atrophy; however, they did not explore the potential correlation between them (19). Because of a lack of clear-cut history of cognition and typical imaging presentation, whether the case presented here really suffers from AD or pre-clinical AD is uncertain. During 5 months of follow-up, the patient exhibited continuous improvements in cognitive function and was in the stage of mild...
cognitive impairment. His son confirmed that his father was only more likely to forget things than the period before the onset of the disease. Based on the patient's recovery, we believe that his symptoms of severe cognitive decline were caused by AE and multiple factors that induced amyloid and Tau abnormalities. At the same time, we hypothesize that the patient might have a chronic mild cognitive dysfunction that was exacerbated by the antibodies. Therefore, we have planned to follow up the patient for a long time, including repeated neuropsychological evaluation, analysis of CSF biomarkers half a year later, and brain MRI examinations at least once a year, to observe changes in the patient's condition and any changes toward AD.

In conclusion, we discussed the clinical characteristics and molecular mechanisms of anti-AMPA encephalitis and its potential interaction with changes in CSF biomarkers of AD, which need to be further investigated. This case provides us with the insight that two pathological processes might coexist. Given the possibility of reversibility and preventing disability, clinicians should be aware of the likelihood of AE when dealing with patients with rapid cognitive decline. However, in these patients and the elderly subjects, in particular, with the possibility of concomitant chronic and progressive cognitive decline, preclinical AD should not be ignored.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

REFERENCES

1. Dubey D, Pittcock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. (2018) 83:166–77. doi: 10.1002/ana.25131
2. Gibson LL, McKeever A, Cullen AE, Nicholson TR, Aarsland D, Zandi MS, et al. Neuronal surface autoantibodies in dementia: a systematic review and meta-analysis. J Neurol. (2020) 1–11. doi: 10.1007/s00415-020-09825-0
3. Höftberger R, van Sonderen A, Leypoldt F, Houghton D, Geschwind M, Gelfand J, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology. (2015) 84:2403–12. doi: 10.1212/WNL.0000000000001682
4. Ömi T, Kinoshita M, Nishikawa A, Tamioka T, Ohmori K, Fukada K, et al. Clinical relapse of Anti-AMPA encephalitis associated with recurrence of thymoma. Intern Med. (2018) 57:1011–3. doi: 10.2169/internalmedicine.9682-17
5. Joubert B, Kerschen P, Zekeridou A, Desestret V, Rogemond V, Chaffois J, et al. Prognosticating autoimmune encephalitis: a systematic review and meta-analysis. JAMA Neurol. (2015) 72:1163–9. doi: 10.1001/jamaneurol.2015.1715
6. Broadley J, Seneviratne U, Beech P, Buzzard K, Butzkueven H, O’Brien T, et al. Systematic review: syndromes, early diagnosis, and treatment in autoimmune encephalitis. Front Neurol. (2018) 9:706. doi: 10.3389/fneur.2018.00706
7. Laurido-Soto O, Brier MR, Simon LE, McCullough A, Bucelli RC, Day GS. Patient characteristics and outcome associations in AMPA receptor encephalitis. J Neurol. (2019) 266:450–60. doi: 10.1007/s00415-018-9153-8
8. Bassani S, Folci A, Zapata J, Passafaro M. AMPAR trafficking in synapse maturation and plasticity. Cell Mol Life Sci. (2013) 70:4411–30. doi: 10.1007/s00018-013-1309-1
9. Höftberger R, van Sonderen A, Leypoldt F, Houghton D, Geschwind M, Gelfand J, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology. (2015) 84:2403–12. doi: 10.1212/WNL.0000000000001682
10. Laurido-Soto O, Brier MR, Simon LE, McCullough A, Bucelli RC, Day GS. Patient characteristics and outcome associations in AMPA receptor encephalitis. J Neurol. (2019) 266:450–60. doi: 10.1007/s00415-018-9153-8
11. Bassani S, Folci A, Zapata J, Passafaro M. AMPAR trafficking in synapse maturation and plasticity. Cell Mol Life Sci. (2013) 70:4411–30. doi: 10.1007/s00018-013-1309-1
12. Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. (2018) 284:643–63. doi: 10.1111/joim.12816
13. Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. (2018) 14:535–62. doi: 10.1016/j.jalz.2018.02.018
14. Baglietto-Vargas D, Prieto GA, Limon A, Forner S, Rodriguez-Ortiz CJ, Ikemura K, et al. Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer’s disease. Aging Cell. (2018) 17:e12791. doi: 10.1111/acel.12791
15. Körtvélyessy P, Priss H, Thurner L, Maetzler W, Vittore-Welligon D, Schultze-Amberger J, et al. Biomarkers of neurodegeneration in autoimmune-mediated encephalitis. Front Neurol. (2018) 9:668. doi: 10.3389/fneur.2018.00668
16. Sandhir R, Gupta S. Molecular and biochemical trajectories from diabetes to Alzheimer’s disease: a critical appraisal. World J Diabetes. (2015) 6:1223–42. doi: 10.4239/wjd.v6.i12.1223

ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

YS and SC: wrote the manuscript and made table and figures. YS, SC, JG, and WX: reviewed the literature. YS, SC, JG, JL, WX, XL, and JC: performed final manuscript review and editing. All authors contributed to the article and approved the submitted.

ACKNOWLEDGMENTS

The authors appreciate the assistance provided by Neuropsychiatry Research Institute of the Affiliated Brain Hospital of Nanjing Medical University in detecting specific antibodies of autoimmune encephalitis.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2021.673347/full#supplementary-material
17. Silva MV, Loures CD, Alves LC, de Souza LC, Borges KB, das Graças Carvalho M. Alzheimer’s disease: risk factors and potentially protective measures. *J Biomed Sci.* (2019) 26:33. doi: 10.1186/s12929-019-0524-y

18. Wallukat G, Prüss H, Müller J, Schimke I. Functional autoantibodies in patients with different forms of dementia. *PLoS ONE.* (2018) 13:e0192778. doi: 10.1371/journal.pone.0192778

19. Edwin Thanarajah S, Prüss H, Warnke C, Barbe MT, Schroeter M, Fink GR, et al. Atypical autoimmune encephalitis with neuropil antibodies against a yet unknown epitope. *Front Neurol.* (2019) 10:175. doi: 10.3389/fneur.2019.00175

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 Song, Chen, Gao, Lu, Xu, Lin and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*